Share this article
Share this article
SHANGHAI and HONG KONG, Dec.18, 2020 /PRNewswire/ Antengene Corporation Limited ( Antengene , SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncology, announced that the National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for ATG-010 (selinexor), an oral Selective Inhibitor of Nuclear Export compound, in combination with bortezomib and dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma (rrMM) in China.
The trial is a Phase 3 randomized, controlled, open-label, multicenter clinical trial, aiming to evaluate the efficacy and safety of ATG-010, bortezomib and dexamethasone (SVd) regimen against bortezomib and dexamethasone (Vd) regimen in Chinese adult patients with rrMM who have received one to three prior lin
Gait Speed May Improve Treatment Decisions in Elderly With Cancer medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
email article
Wide surgical margins did not reduce local recurrence of phyllodes breast tumors, and re-excision of negative margins for benign tumors offered no apparent benefits, according to a review of 550 cases.
The overall recurrence rate was 3.3%, consisting of 15 local recurrences and three distant recurrences. Although wider negative surgical margins (≥2 mm vs
Press release content from Business Wire. The AP news staff was not involved in its creation.
Seattle Cancer Care Alliance Among First Washington Healthcare Providers to Receive COVID-19 Vaccine
December 15, 2020 GMT
Seattle Cancer Care Alliance (SCCA), the only
National Comprehensive Cancer Network (
NCCN )- member cancer center in Washington state, was selected by the Washington State Department of Health to be one of the first 17 sites to receive the recently authorized COVID-19 vaccine. SCCA will receive a portion of the 32,000 doses allotted to Washington State hospitals and will vaccinate its staff, helping to protect the vulnerable patient population that SCCA serves and preserving access to cancer care in the Puget Sound region.
Bispecific Antibodies: The Next Generation of Immunotherapy pharmacytimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmacytimes.com Daily Mail and Mail on Sunday newspapers.